A Study of DCC-2701 in Participants With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Locally Advanced Tumors, Metastatic Solid Tumors, Cancers With MET Genomic Alterations, Cancers With TRK Genomic Alterations

In brief

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.

Key facts

Study ID

NCT02228811

Run by

Deciphera Pharmaceuticals, LLC

People needed

44

Starts

2014-06-01

Expected to finish

2018-01-01

Last updated by the study team

2018-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced or metastatic solid tumor that has progressed or was not responsive to standard therapy
• The cancer has no proven effective therapy
• The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)
• Able to swallow tablets

You may not qualify if…

• Have active central nervous system (CNS) metastasis
• Have an active infection of any kind (fungal, viral, or bacterial)
• Are pregnant or breastfeeding

Where it is running

• University of Colorado Hospital — Aurora, Colorado, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• The Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.